BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A total of 300 new bisphosphonates were screened for their effect on bone resorption in the rat. Among these, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate (BM 21.0955) was selected for detailed investigation. It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroid-ectomized rats at a SC dose as low as 0.001 mg P (0.016 μmol) per kg body weight per day. The compound was thus about 2, 10, 50, and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate, respectively. Intravenous administration was as effective as subcutaneous, and oral administration was 100 times less effective. The effect after one administration decreased with time but was still measurable after 2 weeks. Nonstimulated bone resorption assayed by the urinary excretion of radiolabeled tetracycline from lifelong prelabeled animals was also inhibited. This effect started 3 days after a single dose and was still maximal after 7 days. Histomorphometric analysis of the tibial metaphysis in growing intact rats also showed an inhibition of bone resorption along with an increase in bone mass. The number of osteoclasts increased in animals treated with 0.01 and 0.1 mg P per kg (0.16 and 1.6 μmol/kg) body weight SC but decreased in animals given 1 mg P per kg (16.1 μmol/kg), showing that the inhibition of bone resorption was not due to an inhibition of osteoclast recruitment. No inhibition of mineralization occurred. This new bisphosphonate appears to have great potential for use in human bone disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bisphosphonates do not appear to suppress osteoclastogenesis (129, 140, 141)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [141]
Citations
Cites
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Self-citationHandbook of Experimental Pharmacology
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-1-269_2 · Cited by 727
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Self-citationThe Role of Phosphonates in Living Systems
Hilderbrand (2018) · CRC Press eBooks · doi:10.1201/9781351076470 · Cited by 544
Brown, W. A. B. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)81367-3 · Cited by 495
Schenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Self-citationTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citation
Research works printed but not linked: 8
- Kanis, 1987, Clodronate – a new perspective in the treatment of neoplastic bone disease, Bone (Suppl.), 8, S1
- Burckhardt, 1989, Disodium Pamidronate (APD) in the Treatment of Malignancy-Related Disorders
- Charhon, 1986, Histomorphometric analysis of bone biopsies of baboons treated with “SR 41319BH,” a new diphosphonate (abstract), Calcif Tissue Int, 38, 124
- Bevan, 1988, Bisphosphonate action in the oophorectomized rat: The effects of 2-(3-pyridinyl)-1-hydroxyethylidene-bis(phosphonate) on skeletal metabolism; comparison with etidronate (abstract), J Bone Miner Res (Suppl.), 3, 498
- Valentin-Opran, 1990, Risedronate: Preliminary results of a pharmacologic study in pagetic patients. Twelfth Annual Meeting of the American Society for Bone and Mineral Research, Atlanta, Georgia, August 28–31, 1990 (abstract 182), J Bone Miner Res, 5
- Mühlbauer, 1990, A method for continual monitoring of bone resorption in the rat: Evidence for a diurnal rhythm, Am J Physiol, 259, R679
- Schenk, 1984, Methods of Calcified Tissue Preparation, 1
- Mühlbauer, 1989, 1-Hydroxy-3-(methylpentyl-amino)propylidene-bisphosphonate (BM 21.0955), a potent new inhibitor of bone resorption. Tenth International Conference on Calcium Regulating Hormones and Eleventh Annual Meeting of the American Society for Bone and Mineral Res, Montréal, Québec, Canada, September 9–14, 1989, J Bone Miner Res, 4
Cited by
Items 201–237 of 237
Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update
Pecherstorfer, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802482945 · Cited by 5
“In animal models, ibandronic acid has been shown to be 50 and 500 times more potent than pamidronate and clodronate, respectively [14,15], in inhibiting osteoclast activity [13].”
BackgroundIbandronate in profile: drug characteristics and clinical efficacy
Reginster, J., Neuprez, A., & Bruyère, O. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.941 · Cited by 8
Biochemical Assessment of Bone Metabolism in Rodents
Mühlbauer, R. C. (1994) · Springer eBooks · doi:10.1007/978-3-662-03043-1_11 · Cited by 5
Self-citationDrug Therapy of Hypercalcemia Due to Malignancy
Raue, F., & Pecherstorfer, M. (1994) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-85073-8_9 · Cited by 5
Duvos, C., Scutt, A., & Mayer, H. (1997) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-997-0066-6 · Cited by 5
“8 mM a constant linear increase of calcium was found after challenge with PTH(1-34) during the cultivation period (results not shown).”
BackgroundMethodInfluentialReview of ibandronate in the treatment of osteoporosis
Chapurlat, R. D., & Delmas, P. D. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.3.391 · Cited by 5
“Ibandronate, which has the chemical name 1-hydroxy-3(methylpentylamino)-propilydene bisphosphonate (Figure 1), is an aminobisphosphonate [7] that is a more potent inhibitor of bone resorption than most other compounds.”
BackgroundEpstein, S. (2006) · Current Osteoporosis Reports · doi:10.1007/s11914-006-0010-9 · Cited by 4
Mechanisms of Action of Bisphosphonates as Inhibitors of Bone Resorption
Rogers, M. J., & Russell, R. G. G. (1996) · Medical intelligence unit · doi:10.1007/978-3-662-22505-9_7 · Cited by 5
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
Sambrook, P. N. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.65 · Cited by 4
“In rats, iv ibandronate inhibited bone resorption and increased bone mass in the tibial metaphysis without affecting mineralization (Muhlbauer et al 1991).”
Avaliação do efeito do ibandronato na consolidação de fratura: estudo experimental em coelhos
Guarniero, R., Vaz, C. E. S., de Santana, P. J., Molin, É. D., Braun, J., & Harada, M. S. (2007) · Revista Brasileira de Ortopedia · doi:10.1590/s0102-36162007000800005 · Cited by 3
Optimisation des traitements orthodontiques chez les patients sous biphosphonates
Zahrowski, J. J. (2011) · L Orthodontie Française · doi:10.1051/orthodfr/20010032 · Cited by 3
Ibandronate: A New Oral Bisphosphonate for Postmenopausal Osteoporosis
Guay, D. R. P. (2005) · The Consultant Pharmacist · doi:10.4140/tcp.n.2005.1036 · Cited by 3
Bisphosphonates and Novel Related Structural Classes for Bone Resorption Disorders
Eßwein, A., Bauss, F., Muehlbauer, R., Guenther, H. L., & Bosies, E. (1999) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426509908546170 · Cited by 3
Self-citationDedov, I. I., Rozhinskaya, L. Y., & Belaya, Z. E. (2005) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2005120-30 · Cited by 2
Fleisch, H. A. (1992) · Innovative Aspekte der klinischen Medizin · doi:10.1007/978-3-642-76708-1_9 · Cited by 2
Self-citationChoi, H. Y., Kim, M. J., Kim, Y. H., Noh, Y.-H., Lee, J., Lee, T.-W., Kim, M., & Bae, K. (2014) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2014.22.1.22 · Cited by 2
Ibandronate in the Management of Postmenopausal Osteoporosis
Reginster, J., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2354 · Cited by 3
Overview: Inhibitors of Bone Resorption and Implications for Therapy
Zaidi, M., Alam, A. T., Shankar, V. S., Fairburn, K., Huang, C. L.-H., Moonga, B. S., Panetta, J., Blake, D. R., & Pazianas, M. (1992) · Current Opinion on Therapeutic Patents · doi:10.1517/13543776.2.10.1517 · Cited by 2
Mühlbauer, R. C., & Fleisch, H. A. (1995) · Bone · doi:10.1016/8756-3282(95)00325-8 · Cited by 2
Self-citationIbandronato: Keep Life in Motion
Longo, F., & Mansueto, G. (2004) · Tumori Journal · doi:10.1177/030089160409000230 · Cited by 1
Shiraishi, A. (2014) · Folia Pharmacologica Japonica · doi:10.1254/fpj.143.302 · Cited by 1
Fleisch, H. A. (1994) · Springer eBooks · doi:10.1007/978-3-642-78596-2_12 · Cited by 1
Self-citationIbandronate: a new perspective in the treatment of osteoporosis
Reginster, J. (2005) · Therapy · doi:10.1586/14750708.2.2.179 · Cited by 1
Ibandronate: Once-Monthly and Intravenous Dosing Options for Osteoporosis Treatment
Emkey, R. D. (2006) · Women s Health · doi:10.2217/17455057.2.3.341 · Cited by 1
“This tertiary nitrogen moiety makes the molecule 2-, 10-, 50- and 500-fold more potent at inhibiting bone resorption in vivo than risedronate, alendronate, pamidronate and clodronate, respectively [13].”
BackgroundBisphosphonate Inhibition of Prostate Cancer Cell Invasion, Migration and Cytoskeletal Organization
Virtanen, S. (2010) · UTUPub (University of Turku)
Molecular Pharmacology of Antiresorptive Therapy for Osteoporosis
Adebanjo, O. A., Schwab, E., Sun, L., Pazianas, M., Moonga, B. S., & Zaidi, M. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60153-6 · Cited by 1
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis
Reginster, J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2301 · Cited by 1
“In vivo, this structural conformation confers 2-, 10and 50-fold greater potency than the nitrogen-containing bisphosphonates risedronate, alendronate and pamidronate, respectively, and 500-fold greater potency than the non-nitrogen-containing bisphosphonate, clodronate [43].”
BackgroundInfluentialDie Erfolgsstory einer jungen Wirkstoffklasse: Vom Wasserenthärter zum Pharmakon
Fleisch, H. A. (2001) · Pharmazie in unserer Zeit
Self-citationNieto-Andueza, E. (2007) · Revista Española de Enfermedades Metabólicas Óseas · doi:10.1016/s1132-8460(07)73505-5
Nutrient Metabolism—Research Communication
Buddington, R. K., Buddington, K. K., Deng, D., Hemre, G., & Wilson, R. P. (2002)
Entwicklung der Bisphosphonate bis zur klinischen Anwendung
Bauss, F. (2001) · Steinkopff eBooks · doi:10.1007/978-3-642-57626-3_1 · Cited by 1
Self-citationMalluche, H. H., & Monier‐Faugere, M. (1993) · Springer eBooks · doi:10.1007/978-3-642-78188-9_87
Convegno ESMO 2004 Ibandronato nel Trattamento Delle Metastasi Ossee
Longo, F., & Mansueto, G. (2004) · Tumori Journal · doi:10.1177/030089160409000628
Català, E., & Martinez, M. J. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0261-5.50030-2
Berenson, J. R. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-817-5_13
(2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1410
Bala, Y. (2011) · theses.fr (ABES) · doi:10.70675/9675ed59zf96cz4bfbz8f62za95a95f50fff · Cited by 2
Metadata
- Authors
- Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H.
- Affiliations
- University of Bern (CH)
- Boehringer Mannheim, Mannheim, Germany
- Corresponding author
- Mühlbauer, R.C.
- ORCID
- Janner, M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-09-01
- Volume
- 6
- Issue
- 9
- Pages
- 1003-1011
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2012291531
- Cited by
- 239
- References
- 30
- Citations by year
- 2023: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, risedronate, alendronate, pamidronate, clodronate, bone mass, bone histomorphometry
- MeSH terms
- Risedronic Acid, Pamidronate, Ibandronic Acid, Animals, Benzoates, Bone Resorption, Calcium, Clodronic Acid, Diphosphonates, Injections, Intravenous, Osteoclasts, Retinoids, Etidronic Acid, Spectrophotometry, Atomic, Tetracycline, Thyroxine, Alendronate, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.